Treatment of multidrug-resistant tuberculosis: evidence and controversies.
about
A new strategy to fight antimicrobial resistance: the revival of old antibioticsEuropean union standards for tuberculosis careAmbulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agendaTreatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysisEffect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysisDominant incidence of multidrug and extensively drug-resistant specific Mycobacterium tuberculosis clones in Osaka Prefecture, Japan.Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortalityPlasma drug activity assay for treatment optimization in tuberculosis patients.Drug-resistant tuberculosis: a worldwide epidemic poses a new challengeEpidemiology and treatment of multidrug resistant tuberculosisManagement of MDR-TB: Review of Iran's Experience.Isoniazid inhibits the heme-based reactivity of Mycobacterium tuberculosis truncated hemoglobin NMultidrug-resistant tuberculosis: Treatment and outcomes of 93 patients.Antitubercular drug resistance in four healthcare facilities in North IndiaMultidrug and extensively drug-resistant tuberculosis management: Evidences and controversiesAminoglycoside multiacetylating activity of the enhanced intracellular survival protein from Mycobacterium smegmatis and its inhibition.Aggressive regimens for multidrug-resistant tuberculosis reduce recurrenceDrug resistance patterns in 111 cases of drug-resistant tuberculosis spine.Principles for designing future regimens for multidrug-resistant tuberculosis.Rifampin resistance, Beijing-W clade-single nucleotide polymorphism cluster group 2 phylogeny, and the Rv2629 191-C allele in Mycobacterium tuberculosis strainsManagement of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.
P2860
Q21131083-0AD4E3C7-317F-4712-98AE-B0D9AF6F435FQ26823223-66836980-4C0B-4E20-8A73-C9EAB349DD28Q28472337-870693D3-4746-44F6-B6DF-C4DA66FF0547Q28473126-89EB0C8B-BC1E-41DF-9DC7-8CCE5DBDFD33Q28476110-769E2BE0-B0CE-4EC3-9174-9F2B5BAC4D06Q28476120-5D2AE01D-827D-46FF-82B8-10A8120A1621Q28483178-F69783FD-82A8-4725-8019-D924255C2287Q28487938-FF8A6F3B-3A98-4852-99B7-5E1450120861Q30426583-0CB422E3-152E-41D3-81FD-70AC6D389790Q33595284-594938B2-8442-4453-81E3-CD9271BEA157Q33710690-3F53AFC6-EB91-424B-BDF9-36011BD136F1Q34126714-FD6E06BF-B0AF-4FE7-829A-A9F33C70F08EQ34924586-574956CA-600B-429A-8186-D42AF1F72B09Q35322061-ACEF323D-2871-493C-8F4B-9663137D47DAQ35676541-3FAB71A6-CAB7-4D54-9D72-670A53C7E575Q35966734-A7E53BD8-5D59-4440-A099-80A4706A90EEQ36185972-F9424F14-633D-4472-BB16-BB3DE4D6C85AQ36638826-A8AE6041-6DA3-4417-B055-DCFEABF50A34Q36951876-21E06D54-9901-4F6C-9A50-3293A9C37779Q37398037-598F5905-B178-4A0D-A239-1B200048D026Q41841999-2ACCB0FE-BBCE-4445-8727-5559A7C7CF83Q42715629-DCBF9989-0DD7-4A73-AE09-21B6092460FB
P2860
Treatment of multidrug-resistant tuberculosis: evidence and controversies.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Treatment of multidrug-resistant tuberculosis: evidence and controversies.
@ast
Treatment of multidrug-resistant tuberculosis: evidence and controversies.
@en
type
label
Treatment of multidrug-resistant tuberculosis: evidence and controversies.
@ast
Treatment of multidrug-resistant tuberculosis: evidence and controversies.
@en
prefLabel
Treatment of multidrug-resistant tuberculosis: evidence and controversies.
@ast
Treatment of multidrug-resistant tuberculosis: evidence and controversies.
@en
P1476
Treatment of multidrug-resistant tuberculosis: evidence and controversies
@en
P2093
British Thoracic Society
J A Caminero
P304
P577
2006-08-01T00:00:00Z